Search

everythinglearnresearchcommunity

for

Search:↓

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.

SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.

The models can help find better inhibitors for conditions like baldness and prostate disorders.

New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.

Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.

A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

A new compound may treat benign prostatic hyperplasia better than finasteride.

Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.

Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.

Many patients on new leukemia drugs had mild to moderate skin reactions.

New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.

The compounds tested could potentially treat hair loss and alopecia.

Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.

Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.